China SXT Pharmaceuticals (SXTC) Finished Goods (2021 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Finished Goods for 6 consecutive years, with $639602.0 the latest figure, recorded in Q1 2026.

• Quarterly Finished Goods rose 42.56% year-over-year to $639602.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $639602.0 (up 42.56% YoY) and the FY2026 annual result came in at $639602.0, up 42.56% from the prior year.
• Finished Goods advanced to $639602.0 in Q1 2026 per SXTC's latest filing, from $511307.0 in the prior quarter.
• Over the last five years, Finished Goods for SXTC reached as high as $639602.0 in Q1 2026 and fell as low as $446866.0 in Q1 2023.
• A 5-year average of $546743.8 and a median of $569214.5 in 2022 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2023 — Finished Goods slipped 23.58% — and 2026, when it soared 42.56%.
• Year by year, Finished Goods stood at $588827.0 in 2022, then slipped by 24.11% to $446866.0 in 2023, then jumped by 34.32% to $600251.0 in 2024, then fell by 14.82% to $511307.0 in 2025, then gained by 25.09% to $639602.0 in 2026.
• According to Business Quant data, Finished Goods over the past three periods registered $639602.0, $511307.0, and $448668.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.